SYNERGICE MAKE MORE POSSIBLE
LIVE

Serial Number

98830251

Owner

Strides Pharma Science Limited

Attorney

Zach Gordon

Filing Date

Oct 31, 2024

Add to watchlist:

No watchlists yet
View on USPTO

SYNERGICE MAKE MORE POSSIBLE Trademark

Serial Number: 98830251

SYNERGICE MAKE MORE POSSIBLE is a trademark filed by Strides Pharma Science Limited on October 31, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 35 (Advertising & Business). The application is currently pending registration.

Owner Contact Info

Strides Pharma Science Limited (4 trademarks)

Bilekhalli, Bannerghatta Road
Bangalore 560076 , IN

Entity Type: 99

Trademark Details

Filing Date

October 31, 2024

Registration Date

Not Registered

Published for Opposition

June 3, 2025

Goods & Services

pharmaceutical preparations for treatment of Musculo skeletal pain; pharmaceutical preparations for treatment of cancer; pharmaceutical preparations for treatment of Psychiatric disorders; pharmaceutical preparations for treatment of human immunodeficiency virus (HIV); pharmaceutical preparations for treatment Gastro Intestinal illnesses and disorders; pharmaceutical preparations for treatment of allergies; pharmaceutical preparations for treatment of viral illnesses; pharmaceutical preparations for treatment of bacterial illnesses; pharmaceutical preparations for diabetes management; pharmaceutical preparations for treatment of gout; pharmaceutical preparations for treatment of fungal infections; pharmaceutical preparations for treatment of attention deficit disorder; pharmaceutical preparations for treatment of immune disorders; pharmaceutical preparations for treatment of neurological disorders and neurological illness; pharmaceutical preparations for treatment of cardiovascular illnesses; pharmaceutical preparations for treatment of urological issues; pharmaceutical preparations for treatment of sleep disorders; pharmaceutical preparations for treatment of sexual disorders; pharmaceutical preparations for bronchodilation; pharmaceutical preparations for treatment of thyroid disorders; pharmaceutical preparations for treatment of hormonal disorders; Tablet preparations for medical purposes for treating Musculo skeletal pain, cancer, Psychiatric disorders, human immunodeficiency virus (HIV), Gastro Intestinal illnesses and disorders, allergies, viral illnesses, bacterial illnesses, gout, fungal infections, attention deficit disorder, immune disorders, neurological disorders and neurological illness, cardiovascular illnesses, urological issues, sleep disorders, sexual disorders, bronchodilation, thyroid disorders, hormonal disorders, and managing diabetes; gelatin capsule preparations for medical purposes for treating Musculo skeletal pain, cancer, Psychiatric disorders, human immunodeficiency virus (HIV), Gastro Intestinal illnesses and disorders, allergies, viral illnesses, bacterial illnesses, gout, fungal infections, attention deficit disorder, immune disorders, neurological disorders and neurological illness, cardiovascular illnesses, urological issues, sleep disorders, sexual disorders, bronchodilation, thyroid disorders, hormonal disorders, and managing diabetes; powder preparations for medical purposes for treating Musculo skeletal pain, cancer, Psychiatric disorders, human immunodeficiency virus (HIV), Gastro Intestinal illnesses and disorders, allergies, viral illnesses, bacterial illnesses, gout, fungal infections, attention deficit disorder, immune disorders, neurological disorders and neurological illness, cardiovascular illnesses, urological issues, sleep disorders, sexual disorders, bronchodilation, thyroid disorders, hormonal disorders, and managing diabetes; syrup preparations for medical purposes for treating Musculo skeletal pain, cancer, Psychiatric disorders, human immunodeficiency virus (HIV), Gastro Intestinal illnesses and disorders, allergies, viral illnesses, bacterial illnesses, gout, fungal infections, attention deficit disorder, immune disorders, neurological disorders and neurological illness, cardiovascular illnesses, urological issues, sleep disorders, sexual disorders, bronchodilation, thyroid disorders, hormonal disorders, and managing diabetes; cream preparations for medical purposes for treating Musculo skeletal pain, cancer, Psychiatric disorders, human immunodeficiency virus (HIV), Gastro Intestinal illnesses and disorders, allergies, viral illnesses, bacterial illnesses, gout, fungal infections, attention deficit disorder, immune disorders, neurological disorders and neurological illness, cardiovascular illnesses, urological issues, sleep disorders, sexual disorders, bronchodilation, thyroid disorders, hormonal disorders, and managing diabetes; oral solution preparations for medical purposes for treating Musculo skeletal pain, cancer, Psychiatric disorders, human immunodeficiency virus (HIV), Gastro Intestinal illnesses and disorders, allergies, viral illnesses, bacterial illnesses, gout, fungal infections, attention deficit disorder, immune disorders, neurological disorders and neurological illness, cardiovascular illnesses, urological issues, sleep disorders, sexual disorders, bronchodilation, thyroid disorders, hormonal disorders, and managing diabetes

Business to business services in the nature of generating business leads, business development, providing business information, and business intermediary services in the nature of acting as single point of contact between clients and vendors, all in the field of generic pharmaceuticals

Filing History

TEAS STATEMENT OF USE RECEIVED
Aug 19, 2026 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 29, 2026 EXRA
SOU EXTENSION 1 GRANTED
Jan 28, 2026 EX1G
SOU EXTENSION 1 FILED
Jan 28, 2026 EXT1
SOU TEAS EXTENSION RECEIVED
Jan 28, 2026 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sep 30, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 3, 2025 NPUB
PUBLISHED FOR OPPOSITION
Jun 3, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 28, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 2, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
May 1, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
May 1, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
May 1, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
May 1, 2025 CNEA
ASSIGNED TO EXAMINER
May 1, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 30, 2025 NWOS
NEW APPLICATION ENTERED
Oct 31, 2024 NWAP